Skip to content

MyoVoice to Restore Natural, Hands-free Communication to Individuals With Vocal Impairments

EMG Voice Restoration

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04762043
Enrollment
30
Registered
2021-02-21
Start date
2021-02-12
Completion date
2023-11-08
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Communication Aids for Disabled, Rehabilitation of Speech and Language Disorders, Speech, Alaryngeal, Speech Disorders, Speech Intelligibility, Speech Perception

Brief summary

This study will evaluate the ability of MyoVoice to replace natural speech. Referred to generally as an Augmentative and Alternative Communication (AAC) device, MyoVoice uses electrical signals recorded non-invasively from speech muscles (electromyographic, or EMG, signals) to restore communication for those with vocal impairments that resulted from surgical treatment of laryngeal and oropharyngeal cancers.

Detailed description

Over 7.5 million people worldwide are unable to vocalize effectively. Among these individuals are cancer survivors who underwent oropharyngeal/laryngeal surgery and must rely on AAC systems such as text-to-speech applications or artificial voice prostheses as substitutes for their natural voice. Yet most of these devices struggle to convey the expressive attributes of speech (prosody), leading to poor comprehension and a lack of emotional content. The clinical trial will investigate the feasibility of MyoVoice-a novel AAC device that uses surface EMG signals to extract patterns for understanding vocabulary and expressive attributes from articulatory musculature during silently mouthed speech-to effectively restore conversational capabilities for individuals living with vocal impairments due to surgical treatment of laryngeal and oropharyngeal cancers. Patients who underwent a total laryngectomy will be asked to communicate with a conversational partner by silently mouthing words using MyoVoice. The device performance will be evaluated in terms of its ability to accurately and quickly translate articulatory muscle activity into audible speech. MyoVoice will also be compared to that of conventional electrolaryngeal speech aids (i.e., artificial larynx) to evaluate device ease-of-use, functional efficacy, and social reception.

Interventions

DEVICEExperimental System: MyoVoice

Person-centric augmentative and alternative communication (AAC) system comprising a user-specific set of wearable sensors for capturing articulatory muscle activity and mobile software that provides real-time audible speech outputs.

DEVICEReference System: Electrolarynx

Hand-operated electromechanical device that operates as an artificial larynx to enable a person after laryngectomy to produce speech.

Sponsors

Altec Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Individuals without Laryngectomy (Controls) Inclusion Criteria: * Primary English speaker * No history of speech, language, cognitive, or hearing disorders * Normal hearing (able to pass a bilateral hearing screening using a threshold of 25 decibels (dB) hearing level (HL) at 125, 250, 500, 1000, 2000, 4000, and 8000 Hz based on the American Speech-Language-Hearing Association) * Capable of signed informed consent

Exclusion criteria

* Inability to understand spoken English or follow simple instructions * History of speech, language, cognitive, or hearing disorders * Inability to provide written informed consent 2. Individuals with Laryngectomy Inclusion Criteria: * At least 6 months S/P total laryngectomy * Primary English speaker * Proficient with an electrolarynx (EL) * Sufficiently available and healthy to comply with multiple test sessions lasting 4-6 hours * Capable of signed informed consent

Design outcomes

Primary

MeasureTime frameDescription
Pitch Recognition Accuracy30 mins to 2 hoursPercent accuracy between recognized (sEMG) and ground-truth (acoustic) estimates of fundamental frequency (perceptually known as vocal pitch). Accuracy is estimated on a continuous scale from 0 to 100%.
Loudness Recognition Accuracy30 mins to 2 hoursPercent accuracy between recognized (sEMG) and ground-truth (acoustic) estimates of intensity level (perceptually related to vocal loudness). Accuracy is estimated on a continuous scale from 0 to 100%.
Speech Naturalness30 mins to 1 hourPercent naturalness between MyoVoice and electrolarynx speech samples. Speech naturalness is defined based on one's preference for how \[the audio\] sounds in terms of rate, rhythm, intonation and voice quality. Naturalness is estimated on a continuous scale from 0 to 100%.

Countries

United States

Participant flow

Participants by arm

ArmCount
Development of Speech Corpora
Each participant produces a list of speech tasks that include syllables, phrases, reading passages, and open-ended questions using the MyoVoice system. Myovoice pitch and loudness recognition accuracy of speech is evaluated. Duration: 30 mins to 2 hours.
10
Experimental and Reference Devices for Communication
Each participant listens to speech produced by an experimental (MyoVoice) and reference (electrolarynx) systems that are used to communicate. Participants rate the naturalness of the speech produced from each device (audio files presented in a randomized order). Duration: 30 mins to 1 hour. Experimental System: MyoVoice: Person-centric AAC system comprising a user-specific set of wearable sensors for capturing articulatory muscle activity and mobile software that provides real-time audible speech outputs. Reference System: Electrolarynx: Hand-operated electromechanical device that operates as an artificial larynx to enable a person after laryngectomy to produce speech.
20
Total30

Baseline characteristics

CharacteristicExperimental and Reference Devices for CommunicationTotalDevelopment of Speech Corpora
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
2 Participants2 Participants0 Participants
Age, Categorical
Between 18 and 65 years
18 Participants28 Participants10 Participants
Age, Continuous55 years
STANDARD_DEVIATION 7.3
42 years
STANDARD_DEVIATION 15.58
28 years
STANDARD_DEVIATION 7.65
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants1 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
18 Participants27 Participants9 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
2 Participants2 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants2 Participants0 Participants
Race (NIH/OMB)
White
17 Participants27 Participants10 Participants
Region of Enrollment
United States
20 Participants30 Participants10 Participants
Sex: Female, Male
Female
9 Participants14 Participants5 Participants
Sex: Female, Male
Male
11 Participants16 Participants5 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 20
other
Total, other adverse events
0 / 100 / 20
serious
Total, serious adverse events
0 / 100 / 20

Outcome results

Primary

Loudness Recognition Accuracy

Percent accuracy between recognized (sEMG) and ground-truth (acoustic) estimates of intensity level (perceptually related to vocal loudness). Accuracy is estimated on a continuous scale from 0 to 100%.

Time frame: 30 mins to 2 hours

Population: The sEMG and acoustic data collected from participants in the Development of Speech Corpora arm were used to develop and evaluate an algorithm to predict vocal loudness (acoustic correlate: intensity) from sEMG data. Higher accuracy scores equate to better performance.

ArmMeasureValue (MEAN)Dispersion
Development of Speech CorporaLoudness Recognition Accuracy12.1 Percent agreement to reference loudnessStandard Deviation 3
Primary

Pitch Recognition Accuracy

Percent accuracy between recognized (sEMG) and ground-truth (acoustic) estimates of fundamental frequency (perceptually known as vocal pitch). Accuracy is estimated on a continuous scale from 0 to 100%.

Time frame: 30 mins to 2 hours

Population: The sEMG and acoustic data collected from participants in the Development of Speech Corpora arm were used to develop and evaluate an algorithm to predict vocal pitch (acoustic correlate: fundamental frequency) from sEMG data. Higher accuracy scores equate to better performance.

ArmMeasureValue (MEAN)Dispersion
Development of Speech CorporaPitch Recognition Accuracy7.70 Percent agreement to reference pitchStandard Deviation 1.63
Primary

Speech Naturalness

Percent naturalness between MyoVoice and electrolarynx speech samples. Speech naturalness is defined based on one's preference for how \[the audio\] sounds in terms of rate, rhythm, intonation and voice quality. Naturalness is estimated on a continuous scale from 0 to 100%.

Time frame: 30 mins to 1 hour

Population: Participants in the Experimental and Reference Devices for Communication rated the naturalness of each sample on a visual analog scale from 0 to 100, which 0 anchored at least natural and 100 anchored at most natural. Higher naturalness scores equate to better performance.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental and Reference Devices for CommunicationSpeech NaturalnessMyoVoice66.2 Percent of high naturalness ratingsStandard Deviation 22.6
Experimental and Reference Devices for CommunicationSpeech NaturalnessElectrolarynx9.7 Percent of high naturalness ratingsStandard Deviation 19.8
Experimental and Reference Devices for CommunicationSpeech NaturalnessOverall38.0 Percent of high naturalness ratingsStandard Deviation 35.4
p-value: <0.00195% CI: [53.33, 59.76]Mixed Models Analysis

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026